Hans Wildiers

1.9k total citations · 1 hit paper
33 papers, 1.1k citations indexed

About

Hans Wildiers is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hans Wildiers has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hans Wildiers's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Hans Wildiers is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Hans Wildiers collaborates with scholars based in Belgium, Italy and United States. Hans Wildiers's co-authors include Pierre Scalliet, Diether Lambrechts, S. Monfardini, Denis Lacombe, Ulrich Wedding, Catherine Fortpied, Alexander Ring, Björn Penninckx, Joke Reumers and Stefan Scherer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Hans Wildiers

28 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

2024 52 citations Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Hans Wildiers

Since Specialization

Citations

This map shows the geographic impact of Hans Wildiers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Wildiers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Wildiers more than expected).

Fields of papers citing papers by Hans Wildiers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Wildiers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Wildiers. The network helps show where Hans Wildiers may publish in the future.

Co-authorship network of co-authors of Hans Wildiers

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Wildiers. A scholar is included among the top collaborators of Hans Wildiers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Wildiers. Hans Wildiers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study. 2024 ·Journal of Clinical Oncology ·Matteo Lambertini, Eva Blondeaux, (unknown), Elisa Agostinetto, Anne‐Sophie Hamy, Hee Jeong Kim, Maria Alice Franzoi, Rinat Bernstein‐Molho, Florentine Hilbers, Katarzyna Pogoda, Hans Wildiers, Jyoti Bajpai, Michail Ignatiadis, Halle C. F. Moore, Ann H. Partridge, Kelly‐Anne Phillips, Angela Toss, Christine Rousset‐Jablonski, Carmen Criscitiello, Judith Balmañà	1
2	Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). breakdown → 2024 ·Journal of Clinical Oncology ·Giuseppe Curigliano, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Qingyuan Zhang, Seock‐Ah Im, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Christelle Lévy, William Jacot, (unknown), Jun Ke, Gargi Patel, Aditya Bardia	52
3	Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer 2024 ·Future Oncology ·Valentina Guarneri, (unknown), François P. Duhoux, Daniel Egle, José Á. García-Sáenz, Frédérique Penault‐Llorca, Katri S. Selander, Hans Wildiers, Khalil Zaman, Petra Laeis, Markus Lucerna, Jean‐Yves Pierga	1
4	Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review 2024 ·Breast Cancer Research ·(unknown), Karen Van Baelen, Marion Maetens, Tatjana Geukens, (unknown), Ines Nevelsteen, Ann Smeets, (unknown), P. Neven, Stijn L.W. Koolen, Hans Wildiers, Kevin Punie, Christine Desmedt	6
5	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2− early breast cancer 2021 ·Modern Pathology ·(unknown), Isabelle Vanden Bempt, Hans Wildiers, Ann Smeets, Anne‐Sophie Van Rompuy, Chantal Van Ongeval, Lynn Jongen, Caroline Weltens, Kevin Punie, (unknown), Els Van Nieuwenhuysen, Sileny Han, Ines Nevelsteen, Patrick Neven, Giuseppe Floris	7
6	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study 2021 ·ESMO Open ·(unknown), Kevin Punie, E. Van Eycken, Evandro de Azambuja, Hans Wildiers, François P. Duhoux, Peter Vuylsteke, (unknown), Nancy Van Damme, Didier Verhoeven	4
7	Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3 2021 ·ESMO Open ·(unknown), (unknown), (unknown), Kevin Punie, Ann Smeets, Caroline Weltens, Patrick Neven, Jaak Billen, Annouschka Laenen, Hans Wildiers	15
8	Cancer events in Belgian nursing home residents: An EORTC prospective cohort study 2019 ·Journal of Geriatric Oncology ·Hans Wildiers, Murielle Mauer, Monique Elseviers, (unknown), Sigrid Hatse, Marije E. Hamaker, Frank Buntinx, Jan De Lepeleire, (unknown), Claire Falandry, (unknown), Maryska L.G. Janssen‐Heijnen	3
9	結腸直腸癌高齢患者の高齢者評価の関連性【Powered by NICT】 2017 ·Clinical Colorectal Cancer ·(unknown), (unknown), Cindy Kenis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Koen Milisen, (unknown), (unknown), Hans Wildiers	0
10	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel 2014 ·Breast Cancer Research and Treatment ·Christof Vulsteke, Alena M. Pfeil, Matthias Schwenkglenks, Ruth Pettengell, Thomas D. Szucs, Diether Lambrechts, Marc Peeters, Peter A. van Dam, (unknown), (unknown), P. Neven, R. Paridaens, Hans Wildiers	24
11	Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study 2013 ·Annals of Oncology ·Cindy Kenis, Dominique Bron, Yves Libert, Lore Decoster, Katrien Van Puyvelde, Pierre Scalliet, Pascale Cornette, Thierry Pepersack, S. Luce, Christine Langenaeken, Marika Rasschaert, Sophie Allepaerts, Ruud Van Rijswijk, Koen Milisen, Johan Flamaing, J.‐P. Lobelle, Hans Wildiers	231
12	Breast cancer in women 2013 ·Hans Wildiers, Sabine Stordeur, Joan Vlayen, Rob Scholten, (unknown), Claire Bourgain, Birgit Carly, (unknown), V. Cocquyt, (unknown), (unknown), Mireille Van Goethem, Geert Villeirs, Erik Van Limbergen, (unknown)	1
13	Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab 2012 ·Cancer Research ·Bart Claes, Paul Delmar, Betül T. Yesilyurt, Joke Reumers, Massimiliano Mazzone, Roland Devlieger, Hans Wildiers, Sanne de Haas, Peter Carmeliet, Eric Van Cutsem, Stefan Scherer, Diether Lambrechts	138
14	Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency 2012 ·Carcinogenesis ·Sigrid Hatse, Diether Lambrechts, Annemieke Verstuyf, (unknown), Barbara Brouwers, T. Vandorpe, Olivier Brouckaert, Gilian Peuteman, Annouschka Laenen, Lieve Verlinden, Carsten Kriebitzsch, Anne-Sophie Dieudonné, Robert Paridaens, Patrick Neven, Marie-Rose Christiaens, Roger Bouillon, Hans Wildiers	84
15	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials 2012 ·The Lancet Oncology ·Diether Lambrechts, Bart Claes, Paul Delmar, Joke Reumers, Massimiliano Mazzone, Betül T. Yesilyurt, Roland Devlieger, Chris Verslype, Sabine Tejpar, Hans Wildiers, Sanne de Haas, Peter Carmeliet, Stefan Scherer, Eric Van Cutsem	129
16	A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer 2012 ·Cancer Chemotherapy and Pharmacology ·Robert Paridaens, Olivier Rixe, (unknown), Hans Wildiers, (unknown), Pierre Ferré, Henri Roché	4
17	EORTC elderly task force position paper: Approach to the older cancer patient 2010 ·European Journal of Cancer ·(unknown), Catherine Fortpied, Ulrich Wedding, (unknown), Björn Penninckx, Alexander Ring, Denis Lacombe, S. Monfardini, Pierre Scalliet, Hans Wildiers	231
18	Thyroid dysfunction in patients treated with Sunitinib (SU11248) - A single center retrospective and prospective evaluation 2006 ·Annals of Oncology ·Pascal Wolter, Hans Wildiers, Hans Prenen, (unknown), Herlinde Dumez, Patrick Schöffski	0
19	Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view 2006 ·International Journal of Gynecological Cancer ·Patrick Neven, Robert Paridaens, Frédéric Amant, Hans Wildiers, Patrick Berteloot, Karin Leunen, Ann Smeets, Caroline Weltens, W. Van den Bogaert, Erik Van Limbergen, Marie-Rose Christiaens, Ignace Vergote	2
20	The influence of body composition and hormone replacement therapy (HRT) on progesterone receptor (PR) expression in postmenopausal women with an oestrogen receptor (ER)-positive breast cancer 2006 ·International Journal of Gynecological Cancer ·Tim Van Mieghem, Karin Leunen, Nathalie Pochet, (unknown), Bart De Moor, Frank De Smet, Frédéric Amant, Patrick Berteloot, (unknown), (unknown), M. Drijkoningen, Erik Van Limbergen, Ann Smeets, Hans Wildiers, Robert Paridaens, M-R Christiaens, Ignace Vergote, Patrick Neven	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact